@mmp Aren’t we talking UBT? But I see your point.
In the Phase Ia single-dose trial in healthy subjects, across the 1.0–4.5 mg dose range the mean half-life for each dose arm was 137–170 hours, which supported once-weekly dosing.
That's roughly 5.7–7 days, consistent with once-weekly subcutaneous injection.
Hard to beat the Elora-Tirz stack.